The Future in Ovarian Cancer: Advances in Immunotherapies
- 18 October 2016
- book chapter
- Published by Springer Nature
- p. 143-168
Abstract
No abstract availableKeywords
This publication has 138 references indexed in Scilit:
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced CancerMolecular Therapy, 2012
- Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysisGynecologic Oncology, 2012
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialInternational Journal of Cancer, 2010
- Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rashGynecologic Oncology, 2009
- Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group studyGynecologic Oncology, 2008
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Adoptive immunotherapy for cancer: building on successNature Reviews Immunology, 2006
- The biology of VEGF and its receptorsNature Medicine, 2003
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002